BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bae D, Choi Y, Lee J, Ha N, Suh D, Baek J, Park J, Son W. M-134, a novel HDAC6-selective inhibitor, markedly improved arthritic severity in a rodent model of rheumatoid arthritis when combined with tofacitinib. Pharmacol Rep 2021;73:185-201. [PMID: 33188511 DOI: 10.1007/s43440-020-00188-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Bae D, Lee JY, Ha N, Park J, Baek J, Suh D, Lim HS, Ko SM, Kim T, Som Jeong D, Son WC. CKD-506: A novel HDAC6-selective inhibitor that exerts therapeutic effects in a rodent model of multiple sclerosis. Sci Rep 2021;11:14466. [PMID: 34262061 DOI: 10.1038/s41598-021-93232-6] [Reference Citation Analysis]
2 Li M, Hu W, Wang R, Li Z, Yu Y, Zhuo Y, Zhang Y, Wang Z, Qiu Y, Chen K, Ding Q, Qi W, Zhu M, Zhu Y. Sp1 S-Sulfhydration Induced by Hydrogen Sulfide Inhibits Inflammation via HDAC6/MyD88/NF-κB Signaling Pathway in Adjuvant-Induced Arthritis. Antioxidants 2022;11:732. [DOI: 10.3390/antiox11040732] [Reference Citation Analysis]
3 Fang TJ, Lin CH, Lin YZ, Chiu MH, Li RN, Chan HC, Yeh YT, Yen JH. Lower HDAC6 mRNA expression and promoter hypomethylation are associated with RA susceptibility. J Formos Med Assoc 2021:S0929-6646(21)00480-0. [PMID: 34732304 DOI: 10.1016/j.jfma.2021.10.008] [Reference Citation Analysis]